New medicines to fight treatment resistance in breast and lung cancers
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers
This project aims to create new medications that can help overcome when breast and lung cancers stop responding to current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-11132688 on NIH RePORTER |
What this research studies
Many cancer treatments work well at first, but cancer cells can adapt and become resistant over time, making the treatments less effective. This research focuses on developing new drugs that target specific proteins, called CDK12 and CDK13, which cancer cells use to adapt and survive. By blocking these proteins, we hope to make existing therapies work better and for longer. The goal is to find a safe and effective new drug that can be tested in patients with HER2+ breast cancer, triple-negative breast cancer, and KRAS-driven lung cancer that have become resistant to other treatments.
Who could benefit from this research
Good fit: This foundational research is for patients with HER2+ breast cancer, triple-negative breast cancer, or KRAS-driven lung cancer who may eventually benefit from new therapies designed to overcome drug resistance.
Not a fit: Patients whose cancers are not HER2+ breast, triple-negative breast, or KRAS-driven lung cancer, or who are not experiencing treatment resistance, may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients whose breast or lung cancers have become resistant to current therapies, potentially improving treatment effectiveness and survival.
How similar studies have performed: Other studies have shown that targeting CDK12 and CDK13 is a promising approach to combat acquired drug resistance in cancer.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Duckett, Derek Ronald — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Duckett, Derek Ronald
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.